ERS Genomics Secures New CRISPR Patent
The European Patent Office (EPO) has granted a significant CRISPR/Cas9 patent, EP 4 289 948, to the CVC consortium, including ERS Genomics. This patent features broad claims that cover important components like guide RNAs and their combination with Cas9, enhancing the landscape of gene editing technology.
Strengthening Leadership in CRISPR IP
This new patent is a considerable step forward for ERS Genomics, which is dedicated to providing widespread access to critical intellectual property in the CRISPR field. With over 150 licensees relying on these patents, the validation from EPO solidifies the position of CVC in the competitive CRISPR landscape.
CEO's Perspective on the Patent Grant
John E Milad, the CEO of ERS Genomics, expressed confidence in the patent's implications. He remarked that the granting of EP 4 289 948, which includes extensive claims, reinforces the leadership of CVC in European CRISPR intellectual property. This development provides licensees with greater assurance regarding their operational rights.
Implications for Licensees
The approval of this patent not only protects the existing licensees but also encourages new ones to explore the potential of CRISPR/Cas9 technologies. ERS Genomics ensures that those holding licenses will be able to operate confidently in the evolving research environment without encroaching on intellectual property rights.
Focus on Future Developments
ERS Genomics is looking forward to upcoming CRISPR patent decisions in the United States. Regardless of these outcomes, the robustness of their foundational patents will continue to provide essential protection for their licensees in the CRISPR/Cas9 domain.
About ERS Genomics
Founded to offer access to the key CRISPR/Cas9 intellectual property estate, ERS Genomics licenses the CVC Patents co-owned by Professor Emmanuelle Charpentier. Holding a license to the CVC Patents is vital for conducting research safely using CRISPR/Cas9 across various organisms.
Extensive Coverage of CVC Patents
The CVC Patents comprise over 130 patents worldwide, with more than 50 in the United States alone, protecting over 1,400 claims related to CRISPR technology. This extensive coverage affirms the importance of these patents in supporting ongoing research and development in the life sciences.
Applications of CRISPR Technology
Licenses from ERS Genomics facilitate a wide array of applications beyond human therapeutic use, spanning life sciences research tools, the creation of novel therapeutic targets, and advancement in agricultural science. This expansive range includes the development of cell lines for drug screening, antibody production, and synthetic biology projects focused on biofuels and enzyme production.
Notable Licensees
Among the reputable organizations that have licensed from ERS Genomics are GSK, Merck, Bayer, ThermoFisher Scientific, Corteva, and Charles River Laboratories. These collaborations exemplify the trust and reliance placed in ERS Genomics’ licensing agreements to foster innovation and development in the life sciences and biotechnology sectors.
Frequently Asked Questions
What is the CRISPR/Cas9 patent granted to CVC?
The patent EP 4 289 948 granted to CVC covers key elements essential for CRISPR technology, including guide RNAs and their usage with Cas9.
How does this patent impact ERS Genomics licensees?
This patent provides security and assurance to ERS Genomics' 150+ licensees, reinforcing their rights in the CRISPR landscape.
Who owns the CVC Patents?
The CVC Patents are co-owned by Professor Emmanuelle Charpentier, the University of California, and the University of Vienna.
What applications can benefit from ERS Genomics' licensing?
Licenses cover various applications, including life sciences research, development of therapeutic products, and advancements in agricultural health.
What does the future hold for ERS Genomics?
ERS Genomics is focused on ongoing developments related to CRISPR patenting, with confidence in their foundational patents supporting industry needs.
